Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN.

And retail traders should know.

We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.

So how do we know what this whale just did?

Today, Benzinga's options scanner spotted 28 uncommon options trades for Regeneron Pharmaceuticals.

This isn't normal.

The overall sentiment of these big-money traders is split between 60% bullish and 39%, bearish.

Out of all of the special options we uncovered, 9 are puts, for a total amount of $493,852, and 19 are calls, for a total amount of $1,100,600.

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $940.0 for Regeneron Pharmaceuticals over the last 3 months.

Volume & Open Interest Development

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 63.58 with a total volume of 974.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Regeneron Pharmaceuticals's big money trades within a strike price range of $400.0 to $940.0 over the last 30 days.

Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Where Is Regeneron Pharmaceuticals Standing Right Now?

• With a volume of 539,788, the price of REGN is down -1.31% at $752.12.
• RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
• Next earnings are expected to be released in 86 days.

What The Experts Say On Regeneron Pharmaceuticals:

• Guggenheim has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $935.
• RBC Capital has decided to maintain their Sector Perform rating on Regeneron Pharmaceuticals, which currently sits at a price target of $811.
• EF Hutton downgraded its action to Buy with a price target of $862
• Truist Securities has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1050.
• Morgan Stanley has decided to maintain their Overweight rating on Regeneron Pharmaceuticals, which currently sits at a price target of $927.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.